Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
ClinicalTrials.gov |
Last refreshed on:
|
19 February 2015 |
Main ID: |
NCT00723905 |
Date of registration:
|
25/07/2008 |
Prospective Registration:
|
No |
Primary sponsor: |
|
Public title:
|
Remicade Infusion Management Program
RemiTRAC |
Scientific title:
|
Remicade Infusion Management Program |
Date of first enrolment:
|
August 2005 |
Target sample size:
|
1630 |
Recruitment status: |
Completed |
URL:
|
http://clinicaltrials.gov/show/NCT00723905 |
Study type:
|
Observational |
Study design:
|
Observational Model: Cohort, Time Perspective: Prospective
|
Phase:
|
|
|
Countries of recruitment
|
Canada
| | | | | | | |
Contacts
|
Name:
|
Janssen Inc. Clinical Trial |
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
Janssen Inc. |
| | |
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Subject is a good candidate to receive infliximab as per the Product Monograph
- Subject is prescribed infliximab by an appropriate physician
- Subject receives infusion in a community infusion centre.
- Subject has signed the approved consent form.
Exclusion Criteria:
- Not specified in the protocol
Age minimum:
N/A
Age maximum:
N/A
Gender:
Both
|
Health Condition(s) or Problem(s) studied
|
Arthritis, Rheumatoid
|
Crohn Disease
|
Primary Outcome(s)
|
Type and frequency of infusion reactions
[Time Frame: Up to 7 years]
|
Infusion reaction management approaches
[Time Frame: Up to 7 years]
|
Pre-infusion treatments and efficacy
[Time Frame: Up to 7 years]
|
The number of subjects with adverse events
[Time Frame: Up to 7 years]
|
Secondary ID(s)
|
CR100746
|
P04466
|
Source(s) of Monetary Support
|
Please refer to primary and secondary sponsors
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|